Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy

Circulation

Volumn 112, Issue 4, 2005, Pages 535-543

  Wood, John C ^a   Otto Duessel, Maya ^a   Aguilar, Michelle ^a   Nick, Hanspeter ^b   Nelson, Marvin D ^a   Coates, Thomas D ^a   Pollack, Harvey ^a   Moats, Rex ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anemia; Cardiomyopathy; Iron overload; Magnetic resonance imaging; Thalassemia

Indexed keywords

IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TRANSFUSION; CALIBRATION; CARDIOMYOPATHY; CONTROLLED STUDY; DRY WEIGHT; ENDOCRINE DISEASE; FEMALE; GERBIL; HEART MUSCLE BIOPSY; HEART WEIGHT; IMAGE ANALYSIS; IRON CARDIOMYOPATHY; IRON OVERLOAD; IRON STORAGE; LIVER INJURY; LIVER WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; SICKLE CELL ANEMIA; THALASSEMIA MAJOR;

ANIMALS; BLOOD TRANSFUSION; CALIBRATION; CARDIOMYOPATHIES; FEMALE; GERBILLINAE; HUMANS; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; THALASSEMIA;

EID: 23044475721     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.504415     Document Type: Article

References (43)

1. Greenberg PL, Gordeuk V, Issaragrisil S, Siritanaratkul N, Fucharoen S, Ribeiro RC. Major hematologic diseases in the developing world: new aspects of diagnosis and management of thalassemia, malarial anemia, and acute leukemia. Hemalology (Am Soc Hematol Educ Program). 2001:479-498.
2. Weatherall DJ. Thalassemia in the next millennium: keynote address. Ann NY Acad Sci. 1998;850:1-9.
3. Engle MA, Ehlers KH, O'Loughlin JE, Giardina PJ, Hilgartner MW. Beta thalassemia and heart disease: three decades of gradual progress. Trans Am Clin Climatol Assoc. 1984;96:24-33.
4. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
5. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
6. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574-578.
7. Lerner N, Blei F, Bierman F, Johnson L, Piomelli S. Chelation therapy and cardiac status in older patients with thalassemia major. Am J Pediatr Hematol Oncol. 1990;12:56-60.
8. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol. 1990;84:113-117.
9. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med. 2001;111:349-354.
10. Ehlers KH, Levin AR, Markenson AL, Marcus JR, Klein AA, Hilgartner MW, Engle MA. Longitudinal study of cardiac function in thalassemia major. Ann NY Acad Sci. 1980;344:397-404.
11. Jessup M, Manno CS. Diagnosis and management of iron-induced heart disease in Cooley's anemia. Ann N Y Acad Sci 1998;850:242-250.
12. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-2179.
13. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516-520.
14. Wood JC, Tyszka JM, Ghugre N, Carson S, Nelson MD. Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. Blood. 2004;103:1934-1936,
15. Wood JC, Ghugre N, Carson S, Tyszka JM, Nelson MD, Coates TD. Predictors of abnormal myocardial function and T2* in children and young adults with thalassemia major. Blood. 2003;102:952a. Abstract.
16. Fischer R, Engelhardt R. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet. 2003;361:182-183; author reply 183-184. Letter.
17. St Pierre TG. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet. 2003;361:182: author reply 183-184. Letter.
18. Wood JC, Tyszka JM, Ghugre N, Carson S, Nelson MD, Coates TD. MRI R2 and R2* accurately estimate hepatic iron concentration in transfusion- dependent thalassemia and sickle-cell disease. Blood. 2003;102:414a.
19. Olson LJ, Edwards WD, Holmes DR Jr, Miller FA Jr, Nordstrom LA, Baldus WP. Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. J Am Coll Cardiol. 1989;13:116-120.
20. Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI, Peters TJ. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res. 1980;14:719-724.
21. Yang T, Dong WQ, Kuryshev YA, Obejero-Paz C, Levy MN, Brittenham GM, Kiatchoosakun S, Kirkpatrick D, Hoit BD, Brown AM. Bimodal cardiac dysfunction in an animal model of iron overload. J Lab Clin Med. 2002;140:263-271.
22. Obejero-Paz CA, Yang T, Dong WQ, Levy MN, Brittenham GM, Kuryshev YA, Brown AM. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med. 2003;141:121-130.
23. Laurita KR, Chuck ET, Yang T, Dong WQ, Kuryshev YA, Brittenham GM, Rosenbaum DS, Brown AM. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. J Lab Clin Med. 2003;142:83-89.
24. Kuryshev YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, Brown AM. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes: implications for the arrhythmogenesis of human siderotic heart disease. Circulation. 1999; 100:675-683.
25. Zuyderhoudt FM, Sindram JW, Marx JJ, Jorning GG, van Gool J. The amount of ferritin and hemosiderin in the livers of patients with iron-loading diseases. Hepatology. 1983;3:232-235.
26. Riffenburgh R. Statistics in Medicine. London, UK: Academic Press; 1999.
27. St Pierre TG, Tran KC, Webb J, Macey DJ, Heywood BR, Sparks NH, Wade VJ, Mann S, Pootrakul P. Organ-specific crystalline structures of ferritin cores in beta-thalassemia/hemoglobin E. Biol Met. 1991;4: 162-165.
28. Liu P, Henkelman M, Joshi J, Hardy P, Butany J, Iwanochko M, Clauberg M, Dhar M, Mai D, Waien S, Olivieri N. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. Can J Cardiol. 1996;12: 155-164.
29. Wang ZJ, Lian L, Chen Q, Zhao H, Asakura T, Cohen AR. 1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. Radiology. 2005;234:749-755.
30. Wacker CM, Bock M, Hartlep AW, Beck G, van Kaick G, Ertl G, Bauer WR, Schad LR. Changes in myocardial oxygenation and perfusion under pharmacological stress with dipyridamole: assessment using T*2 and T1 measurements. Magn Reson Med. 1999;41:686-695.
31. Clark PR, Chua-Anusorn W, St Pierre TG. Proton transverse relaxation rate (R2) images of iron-loaded liver tissue: mapping local tissue iron concentrations with MRI [published erratum appears in Magn Reson Med. 2003;49:1201]. Magn Reson Med. 2003;49:572-575.
32. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med. 1971;51:209-221.
33. Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol. 1987;10: 1239-1243.
34. St Pierre TG, Clark PR, Chua-Anusorn W. Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed. 2004;17: 446-458.
35. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18:33-39.
36. Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, Wonke B, Pennell DJ. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of lissue iron in thalassemia. J Magn Reson Imaging. 2003;18:616-620.
37. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855-861.
38. Tanimoto A, Oshio K, Suematsu M, Pouliquen D, Stark DD. Relaxation effects of clustered particles. J Magn Reson Imaging. 2001;14:72-77.
39. Weisskoff RM, Zuo CS, Boxennan JL, Rosen BR. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med. 1994;31:601-610.
40. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with desferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003; 101:4632-4639.
41. Tipnis UR, He GY, Khan MF. Differential induction of polyamine oxidase activity in liver and heart of iron-overloaded rats. J Toxicol Environ Health. 1997;51:235-244.
42. Schwartz KA, Fisher J, Adams ET. Morphologic investigations of the guinea pig model of iron overload. Toxicol Pathol. 1993;21:311-320.
43. Bulte JW, Brooks RA, Moskowitz BM, Bryant LH Jr, Frank JA. Relaxometry and magnetometry of the MR contrast agent MION-46L. Magn Reson Med. 1999;42:379-384.